In December 2023, Novogene officially announced the establishment of its new laboratory in the Innovation and Start-up Center for Biotechnology (IZB) in Munich, Germany, reinforcing its global localization strategy and further enhancing its service capabilities in the European region.
Situated in Martinsried, the Innovation and Start-up Center for Biotechnology (IZB) stands as a forefront biotechnology hub in Europe, housing more than 40 biotech start-ups. Novogene anticipates the full operational launch of its IZB lab in early 2024, and the deployment of this new laboratory is also a crucial component of Novogene’s global localization strategy.
At present, Novogene has strategically positioned laboratories across the globe, including in the United States, the United Kingdom, Singapore, and beyond. This global presence brings highly optimized processes, combined with expert local staff, to deliver an industry-leading service to the scientific community worldwide.
Tingting Zhou, Vice President of Novogene Europe, said: “We are very excited to join the IZB eco-system. This new lab will not only expand our capacity but also enable us to collaborate more closely with researchers and innovators in biotechnology across Europe.”
Dr. Peter Hanns Zobel, Managing Director of IZB, added: "We are delighted Novogene has chosen our dynamic biotech center for their new genomics facility. The inclusion of Novogene on our campus represents an important new collaboration. Their expertise in genomic services will greatly complement the diverse and cutting-edge scientific activities at IZB and enhance the research and innovation potential of our network of biotech companies and academic institutions."
Novogene is a pioneer in creating applications using cutting-edge molecular biology technology and high-performance computing for research in the fields of life science and human health. Novogene delivers unsurpassed data quality to support our customers’ research goals. We are a world leader in NGS services, with thousands of employees and multiple locations across the globe. Novogene has strong scientific expertise, nearly 20,000 SCI articles with a total impact factor of nearly 120,000, including publications in first tiers journals such as Cell, Nature and Science.
As the largest NGS service provider headquartered in Beijing with branches in Hong Kong China, US, UK, Singapore, Netherlands, and Japan, Novogene was founded in 2011 and has been growing rapidly over the past few years. Novogene has genomic sequencing labs in the US, China, Singapore, UK and the GER. www.novogene.com
About the Innovation and Start-up Center for Biotechnology (IZB) in Martinsried near MunichThe Fördergesellschaft IZB GmbH, founded in 1995, operates the Innovation and Start-up Centers for Biotechnology in Planegg-Martinsried and Freising-Weihenstephan and has developed into a leading biotechnology center. 40 biotech companies and five life science firms with over 700 employees are currently based on 26,000 m2. Here, work is being done on developing drugs for the most serious diseases, such as cancer, Alzheimer’s, and various autoimmune diseases. A key criterion for the success of the IZBs is the physical proximity to cutting-edge research on the Martinsried/Grosshadern campus and the Weihenstephan campus. The new infrastructure measures such as the Faculty Club G2B (Gateway to Biotech), the IZB Residence CAMPUS AT HOME, the Elhardt chemistry college, the two kindergartens Bio Kids and Bio Kids2 as well as the two restaurants SEVEN AND MORE, and THE BOWL Food Lounge are also location factors that are highly valued by the founders of the company. Successful companies that emerged from the IZB include Corimmun (today Janssen-Cilag), Crlelux (today Wuxxi AppTec), Exosome Diagnostics (bought by Bio-Techn), ibidi, Immunic Therapeutics, Medigene, Micromet (today Amgen), MorphoSys, Octopharma or Rigontec (now MSD) as well as SIRION Biotech (today Perkin Elmer). More information at www.izb-online.com.
The field is required.